What is the appropriate starting dose, titration schedule, and monitoring plan for cinacalcet in a patient with secondary hyperparathyroidism on dialysis (or primary hyperparathyroidism who is not a surgical candidate)?

Cinacalcet Dosing and Management

For secondary hyperparathyroidism in dialysis patients, start cinacalcet at 30 mg once daily with food, titrate every 2-4 weeks through sequential doses (30,60,90,120,180 mg daily) targeting iPTH 150-300 pg/mL, and monitor calcium/phosphorus within 1 week and iPTH at 1-4 weeks after each dose change. 1

Starting Dose and Administration

Take cinacalcet with food or shortly after a meal as a whole tablet—never crush, chew, or divide. 1

For Secondary Hyperparathyroidism (Dialysis Patients)

• Starting dose: 30 mg once daily 1
• This applies to both hemodialysis and peritoneal dialysis patients 2
• Japanese populations may start at 25 mg due to higher adverse event rates at 50 mg 3

For Primary Hyperparathyroidism or Parathyroid Carcinoma

• Starting dose: 30 mg twice daily 1
• These patients are non-surgical candidates or have contraindications to parathyroidectomy

Titration Schedule

Titrate no more frequently than every 2-4 weeks through the following sequential doses 1:

For dialysis patients (once daily dosing):

• 30 mg → 60 mg → 90 mg → 120 mg → 180 mg daily

For primary hyperparathyroidism/parathyroid carcinoma (divided dosing):

• 30 mg twice daily → 60 mg twice daily → 90 mg twice daily → 90 mg 3-4 times daily

The target iPTH for dialysis patients is 150-300 pg/mL 1. For primary hyperparathyroidism, titrate to normalize serum calcium 1.

Monitoring Plan

Initial Monitoring (First Month)

• Serum calcium and phosphorus: within 1 week after initiation or dose adjustment 1
• iPTH: 1-4 weeks after initiation or dose adjustment 1
• Measure iPTH no earlier than 12 hours after dosing 1

Maintenance Monitoring

Once the maintenance dose is established 1:

• Dialysis patients with secondary hyperparathyroidism: monthly calcium checks
• Primary hyperparathyroidism/parathyroid carcinoma: calcium every 2 months
• iPTH: monthly for at least 3 months, then every 3 months once target achieved 4

Managing Hypocalcemia

If calcium falls to 8.4-7.5 mg/dL or mild symptoms occur:

• Increase calcium-containing phosphate binders
• Increase vitamin D sterols
• Continue cinacalcet 1

If calcium drops below 7.5 mg/dL or symptoms persist:

• Withhold cinacalcet until calcium reaches ≥8 mg/dL and symptoms resolve
• Restart at the next lowest dose 1

Clinical Context and Evidence Quality

Efficacy Evidence

High-quality evidence shows cinacalcet effectively reduces PTH (43% reduction) and prevents parathyroidectomy (RR 0.49) in dialysis patients 5. In trials, 43% of patients achieved target iPTH ≤250 pg/mL versus 5% with placebo 6. Early response (>50% PTH reduction within 1 month) predicts better long-term outcomes, with 90% of early responders achieving target iPTH 7.

Mortality and Cardiovascular Outcomes

Cinacalcet has little or no effect on all-cause mortality (RR 0.97) or cardiovascular death in high-quality evidence 5. However, a 2024 observational trial emulation suggested lower PTH targets may reduce mortality (HR 0.71) and cardiovascular hospitalization (HR 0.78) 8.

Adverse Effects

Expect frequent gastrointestinal side effects 5:

• Nausea: RR 2.05 (affects ~150/1000 patients annually)
• Vomiting: RR 1.97
• Hypocalcemia: RR 7.38 (affects ~60/1000 patients annually)
• Most GI symptoms are mild-to-moderate and transient 6, 2

Guideline Recommendations

The evidence supports restricted use, not routine administration. Current guidelines recommend cinacalcet should be limited to patients with elevated PTH refractory to standard therapy (vitamin D and phosphate binders), with normal or high calcium, and in whom parathyroidectomy is contraindicated 5. The UK NICE guidance explicitly states cinacalcet should not be used for routine treatment of elevated PTH 5.

For primary hyperparathyroidism, cinacalcet reduces calcium by ~0.4 mmol/L with normalization in 75% of patients, though PTH normalization is rarely achieved 9. In the specific context of X-linked hypophosphatemia, cinacalcet should be used with extreme caution due to severe adverse effects including hypocalcemia and QT prolongation 10.

Practical Considerations

Cinacalcet can be combined with vitamin D sterols and phosphate binders 1. The drug reduces hypercalcemia risk (RR 0.23) 5, making it useful when vitamin D causes problematic calcium elevation. However, combining cinacalcet with vitamin D does not fully prevent the calcium-lowering effect of cinacalcet 11.

Switching from etelcalcetide: Discontinue etelcalcetide for at least 4 weeks, ensure corrected calcium is at or above the lower limit of normal, then start cinacalcet at 30 mg once daily 1.

Pediatric use: In children under 5 years on dialysis, cinacalcet can be effective starting at ~0.55 mg/kg/day (average 6.2 mg daily), with significant PTH reduction and minimal side effects 12. However, this is off-label use requiring careful monitoring.